multiple myeloma
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...
Advertisement
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
The data were from the phase III DETERMINATION trial...
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Advertisement
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.